Celldex Therapeutics, Inc.
- Market cap
- $2.99B
- 52w range
- $22.10 - $45.14
- Beta
- 0.90
- Sector
- Healthcare
- Data quality
- 83/100
- fair value estimate
- $15.22
- Margin of safety
- -52.7%
- Moat score
- 15/100
- Return on equity
- -48.9%
- Revenue growth
- -97.8%
- Analyst target
- $57.07
- Target upside
- +77.3%
- Analysts
- 15
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Valuation
Derived from filed metrics · High confidence (83% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).